KPV (5mg)

Research Overview

A tripeptide derived from the C-terminal end of alpha-MSH. Unlike the parent molecule, KPV lacks melanocortin receptor binding but retains potent anti-inflammatory signaling, making it a focus of GI and dermatological research.

Origin: C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH)

Mechanism of Action

• NF-κB inhibition (independent of MC receptors)

• Intracellular PEP-T1 transporter uptake

• Inflammatory cytokine suppression (TNF-α, IL-6, IL-1β)

• Direct antimicrobial activity

Primary Research Areas

• Inflammatory bowel conditions

• Dermatitis

• Antimicrobial defense

• Mucosal healing

Key Published Findings

• Reduced colonic inflammation in DSS-colitis mouse model (Dalmasso et al., 2008)

• Exhibited direct antimicrobial activity against S. aureus and C. albicans

• Transported into intestinal epithelial cells via PEP-T1 transporter

Research Protocol

Commonly studied routes: Oral, Topical, Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.

Storage

-20°C lyophilized, 2-8°C reconstituted

Important Notice

KPV (5mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.